Are Cyclin‐Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?

This letter to the editor remarks on recently reported results of the PALBONET study and describes reasons why it may be too early to eliminate CDK4/6 inhibitors as an option for the treatment of neuroendocrine neoplasms.

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Pusceddu, Sara, Corti, Francesca, Milione, Massimo, Centonze, Giovanni, Prinzi, Natalie, Torchio, Martina, de Braud, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Letters to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418349/
https://ncbi.nlm.nih.gov/pubmed/32436279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0298
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados